What pharmacologic options can lower glutamate, increase dopamine, and regulate GABA in a patient who cannot tolerate selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) but benefits from dextromethorphan (DXM) and agmatine sulfate?

Pharmacologic Options for Glutamate Modulation, Dopamine Enhancement, and GABA Regulation in SSRI/SNRI-Intolerant Patients

Based on your positive response to DXM and agmatine, the most evidence-supported FDA-approved option is dextromethorphan-bupropion (Auvelity), which combines glutamate modulation with dopaminergic effects and is specifically approved for major depressive disorder. 1, 2

Primary Recommendation: Dextromethorphan-Bupropion (Auvelity)

This combination directly addresses your neurochemical targets:

• Glutamate lowering: Dextromethorphan acts as an NMDA receptor antagonist, attenuating glutamate neurotoxicity 3 and providing rapid antidepressant effects through glutamatergic modulation 1
• Dopamine enhancement: Bupropion inhibits dopamine and norepinephrine reuptake, directly increasing dopaminergic activity
• FDA approval: Specifically approved for MDD in 2022, representing a validated alternative to SSRI/SNRI therapy 1, 2

Your positive response to DXM suggests you will likely respond well to this formulation, as it leverages the same glutamatergic mechanism you've already found beneficial.

Alternative Glutamatergic Options

Esketamine (Spravato)

If Auvelity proves insufficient:

• Mechanism: Potent NMDA receptor antagonist with robust glutamate modulation 4, 2
• FDA-approved for treatment-resistant depression (2019) 1
• Administration: Intranasal, requires in-office monitoring
• Evidence: Strongest clinical trial data among glutamatergic agents 4

Caveat: More intensive monitoring requirements and dissociative side effects compared to oral agents.

Agmatine's Mechanistic Support

Your positive response to agmatine aligns with research showing it:

• Modulates NMDA receptors and blocks glutamate neurotoxicity 5, 6
• Enhances dopamine levels in the striatum 5
• Regulates nitric oxide pathways that influence neurotransmitter balance 5, 6
• Acts as a neuromodulator across multiple receptor systems including α2-adrenoceptors and imidazoline receptors 6

This suggests your neurochemistry responds favorably to NMDA antagonism and dopaminergic enhancement—the exact profile of dextromethorphan-bupropion.

GABA Regulation Considerations

The glutamate-GABA balance is interconnected:

• Endogenous glutamate increases GABA through AMPA/KA receptor activation 7
• NMDA receptor modulation (via DXM/agmatine) indirectly influences GABAergic tone 7
• Glutamatergic agents like ketamine and DXM normalize GABA-glutamate imbalances seen in depression 2

Important: Direct GABA modulators (like neurosteroid brexanolone) require IV administration and intensive monitoring 2, making them impractical for outpatient management.

Practical Algorithm

1. Start with Auvelity (dextromethorphan-bupropion)

   • Leverages your known DXM response
   • Oral administration, outpatient-friendly
   • Addresses glutamate, dopamine, and indirectly GABA

2. If partial response: Consider continuing agmatine sulfate as adjunct

   • Preclinical evidence supports NMDA modulation 5, 6
   • May synergize with DXM's glutamatergic effects

3. If inadequate response: Escalate to esketamine (Spravato)

   • More potent NMDA antagonism 4
   • Requires office-based administration

4. Avoid: SSRIs, SNRIs (duloxetine, venlafaxine) given your documented intolerance 8

Critical Warnings

Serotonin syndrome risk: While you're avoiding SSRIs/SNRIs, be aware that combining multiple agents (DXM, bupropion, agmatine) theoretically increases serotonin syndrome risk 9. Monitor for agitation, hyperthermia, neuromuscular symptoms.

CYP2D6 interactions: Both DXM and bupropion interact with this enzyme system 9. Avoid strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) which could increase DXM levels dangerously.

Cardiovascular monitoring: Bupropion can increase blood pressure; baseline and periodic monitoring recommended, especially given your dopaminergic focus 8.

Why Not Other Options

• Tricyclic antidepressants (nortriptyline, desipramine): While they modulate multiple neurotransmitters 8, they don't specifically target glutamate and carry significant cardiac risks
• Gabapentin/pregabalin: Primarily for neuropathic pain 8, not depression, and don't address your dopamine/glutamate targets
• Investigational NMDA modulators (apimostinel, D-cycloserine): Lack FDA approval and robust efficacy data 4, 2

The evidence strongly supports Auvelity as your next step, given it's FDA-approved, targets your specific neurochemical profile, and builds on your documented DXM response.